Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cerevel Therapeutics Holdings, Inc.CERE · Entity 15182 | Chief Financial Officer | February 03, 2021 | February 05, 2021 |
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | EVP & Chief Financial Officer | May 15, 2019 | May 17, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cerevel Therapeutics Holdings, Inc.
Report date February 03, 2021 · Filed February 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.70 · Expires 2031-02-03 | Direct | 216,718 |
Reported balance
After 2021-02-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-03 · Grant · Acquired 216,718 · Balance 216,718 F1: 25% of this option shall vest and become exercisable on February 3, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option shall vest and become exercisable on February 3, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
SANGAMO THERAPEUTICS, INC
Report date May 15, 2019 · Filed May 17, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,512 |
Reported balance
After 2019-05-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-05-15 · Exercise / conversion · Acquired 5,000 · Balance 30,512 |
| Common StockSEC Table I · non-derivative | Direct | 25,512 |
Reported balance
After 2019-05-15 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2019-05-15 · Sale · Disposed 5,000 · Balance 25,512 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F2: Includes 4,833 shares subject to restricted stock units granted on January 24, 2018 that will vest in two (2) remaining equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Additionally, this amount includes 19,250 shares subject to restricted stock units granted on February 25, 2019 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.55 · Expires 2027-02-27 | Direct | 125,000 |
Reported balance
After 2019-05-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-05-15 · Exercise / conversion · Disposed 5,000 · Balance 125,000 F3: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from February 27, 2017, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017.
F2: Includes 4,833 shares subject to restricted stock units granted on January 24, 2018 that will vest in two (2) remaining equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Additionally, this amount includes 19,250 shares subject to restricted stock units granted on February 25, 2019 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates.
F3: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from February 27, 2017, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Theseus Pharmaceuticals, Inc.
Report date February 14, 2024 · Filed February 14, 2024
Section 16 reporting ended · disclosed 2024-02-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-02-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-14 · Disposition to issuer · Disposed 3,250 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 22, 2023, by and among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent") and Concentra Merger Sub II, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of February 14, 2024 (the "Effective Time") with the Issuer surviving the merger. F2: Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share. F3: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) $4.05 per Share in cash (the "Cash Amount"), without interest and subject to any withholding of taxes; and (ii) one non-transferable contractual contingent value right per Share (each, a "CVR") subject to such Issuer RSU, which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.03 | Direct | 0 |
Reported balance
After 2024-02-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-14 · Disposition to issuer · Disposed 99,634 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer Stock Option with an exercise price that is less than the Cash Amount was cancelled and converted into the right to receive (i) a cash payment equal to the product of (A) the excess, if any, of the Cash Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time and (ii) one CVR for each Share underlying such Issuer Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 22, 2023, by and among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent") and Concentra Merger Sub II, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of February 14, 2024 (the "Effective Time") with the Issuer surviving the merger.
F2: Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share.
F3: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) $4.05 per Share in cash (the "Cash Amount"), without interest and subject to any withholding of taxes; and (ii) one non-transferable contractual contingent value right per Share (each, a "CVR") subject to such Issuer RSU, which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal.
F4: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer Stock Option with an exercise price that is less than the Cash Amount was cancelled and converted into the right to receive (i) a cash payment equal to the product of (A) the excess, if any, of the Cash Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time and (ii) one CVR for each Share underlying such Issuer Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2024 Filed Feb 14, 2024 16:03 UTC | Theseus Pharmaceuticals, Inc. THRX · Entity 94301 | Disposition to issuerStock Option (Right to Buy) · Derivative | 99,634 | Not disclosed Strike: $4.03 | Not disclosed |
DisclosureSEC source: 0001104659-24-023581 · tm246087-7_4seq1.xml · derivative · entry 2 Yi Kathy · CIK 0001697802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 99,634 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer Stock Option with an exercise price that is less than the Cash Amount was cancelled and converted into the right to receive (i) a cash payment equal to the product of (A) the excess, if any, of the Cash Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time and (ii) one CVR for each Share underlying such Issuer Stock Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer Stock Option with an exercise price that is less than the Cash Amount was cancelled and converted into the right to receive (i) a cash payment equal to the product of (A) the excess, if any, of the Cash Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time and (ii) one CVR for each Share underlying such Issuer Stock Option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer Stock Option with an exercise price that is less than the Cash Amount was cancelled and converted into the right to receive (i) a cash payment equal to the product of (A) the excess, if any, of the Cash Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time and (ii) one CVR for each Share underlying such Issuer Stock Option. Read SEC document |
| February 14, 2024 Filed Feb 14, 2024 16:03 UTC | Theseus Pharmaceuticals, Inc. THRX · Entity 94301 | Disposition to issuerRestricted Stock Units · Derivative | 3,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-023581 · tm246087-7_4seq1.xml · derivative · entry 1 Yi Kathy · CIK 0001697802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,250 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 22, 2023, by and among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent") and Concentra Merger Sub II, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of February 14, 2024 (the "Effective Time") with the Issuer surviving the merger. F2 · derivative.exercise_price: Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share. F3 · price: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) $4.05 per Share in cash (the "Cash Amount"), without interest and subject to any withholding of taxes; and (ii) one non-transferable contractual contingent value right per Share (each, a "CVR") subject to such Issuer RSU, which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) $4.05 per Share in cash (the "Cash Amount"), without interest and subject to any withholding of taxes; and (ii) one non-transferable contractual contingent value right per Share (each, a "CVR") subject to such Issuer RSU, which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) $4.05 per Share in cash (the "Cash Amount"), without interest and subject to any withholding of taxes; and (ii) one non-transferable contractual contingent value right per Share (each, a "CVR") subject to such Issuer RSU, which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal. Read SEC document |
| June 13, 2023 Filed Jun 13, 2023 17:30 UTC | Theseus Pharmaceuticals, Inc. THRX · Entity 94301 | GrantRestricted Stock Unit · Derivative | 3,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001745020-23-000039 · wk-form4_1686691788.xml · derivative · entry 2 Yi Kathy · CIK 0001697802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,250 Underlying: Common Stock · 3,250 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001 per share, when vested. F3 · derivative.exercise_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied on the earlier of (i) June 9, 2024 or (ii) the day prior to the date of the issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service with the issuer on such vesting date. The RSUs have no expiration date. F3 · derivative.expiration_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied on the earlier of (i) June 9, 2024 or (ii) the day prior to the date of the issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service with the issuer on such vesting date. The RSUs have no expiration date. Read SEC document |
| June 13, 2023 Filed Jun 13, 2023 17:30 UTC | Theseus Pharmaceuticals, Inc. THRX · Entity 94301 | GrantStock Option (right to buy) · Derivative | 19,500 | $0.00 Strike: $9.61 | $0.00 |
DisclosureSEC source: 0001745020-23-000039 · wk-form4_1686691788.xml · derivative · entry 1 Yi Kathy · CIK 0001697802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2033-06-12 F1 · derivative.exercise_date: The options are subject to a service-based vesting requirement, which shall be satisfied on the earlier of (i) June 9, 2024 or (ii) the day prior to the date of the issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service with the issuer on such vesting date. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 20:13 UTC | Theseus Pharmaceuticals, Inc. THRX · Entity 94301 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001104659-22-070663 · tm2218348-3_4seq1.xml · derivative · entry 1 Yi Kathy · CIK 0001697802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The options are subject to a service-based vesting requirement, which shall be satisfied on the earlier of (i) June 10, 2023 or (ii) the day prior to the date of the issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service with the issuer on such vesting date. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 19:00 UTC | Theseus Pharmaceuticals, Inc. THRX · Entity 94301 | GrantStock Option (right to buy) · Derivative | 22,678 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-21-039758 · doc4.xml · derivative · entry 1 Yi Kathy · CIK 0001697802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,678 Underlying: Common Stock · 22,678 shares Expires 2031-10-05 F1 · derivative.exercise_date: The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 1/36th of the options vesting monthly after October 6, 2021, subject to the Reporting Person's continuous service with the issuer. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 18:42 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 216,718 | $0.00 Strike: $12.70 | $0.00 |
DisclosureSEC source: 0000899243-21-005091 · doc4.xml · derivative · entry 1 Yi Kathy · CIK 0001697802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,718 Underlying: Common Stock · 216,718 shares Expires 2031-02-03 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 3, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| October 28, 2020 Filed Oct 30, 2020 20:19 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 78,534 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0000899243-20-030033 · doc4.xml · derivative · entry 1 Yi Kathy · CIK 0001697802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,534 Underlying: Common Stock · 78,534 shares Expires 2030-10-28 F1 · derivative.exercise_date: 50% of this option shall vest and become exercisable on October 28, 2022, with the remainder vesting in two (2) equal annual installments thereafter. Read SEC document |
| May 15, 2019 Filed May 17, 2019 21:41 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-19-031065 · doc4.xml · derivative · entry 3 Yi Kathy · CIK 0001697802 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 5,000 shares Expires 2027-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from February 27, 2017, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| May 15, 2019 Filed May 17, 2019 21:41 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,000 | $10.00 | $50,000.00 |
DisclosureSEC source: 0001209191-19-031065 · doc4.xml · nonDerivative · entry 2 Yi Kathy · CIK 0001697802 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,512 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F2 · balance_after: Includes 4,833 shares subject to restricted stock units granted on January 24, 2018 that will vest in two (2) remaining equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Additionally, this amount includes 19,250 shares subject to restricted stock units granted on February 25, 2019 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Read SEC document |
| May 15, 2019 Filed May 17, 2019 21:41 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,000 | $4.55 | $22,750.00 |
DisclosureSEC source: 0001209191-19-031065 · doc4.xml · nonDerivative · entry 1 Yi Kathy · CIK 0001697802 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 23:27 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-19-024836 · doc4.xml · derivative · entry 3 Yi Kathy · CIK 0001697802 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 5,000 shares Expires 2027-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from February 27, 2017, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 23:27 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,000 | $12.11 | $60,550.00 |
DisclosureSEC source: 0001209191-19-024836 · doc4.xml · nonDerivative · entry 2 Yi Kathy · CIK 0001697802 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,512 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F2 · balance_after: Includes 4,833 shares subject to restricted stock units granted on January 24, 2018 that will vest in two (2) remaining equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Additionally, this amount includes 19,250 shares subject to restricted stock units granted on February 25, 2019 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 23:27 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,000 | $4.55 | $22,750.00 |
DisclosureSEC source: 0001209191-19-024836 · doc4.xml · nonDerivative · entry 1 Yi Kathy · CIK 0001697802 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 23:35 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-19-020126 · doc4.xml · derivative · entry 3 Yi Kathy · CIK 0001697802 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 5,000 shares Expires 2027-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from February 27, 2017, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 23:35 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,000 | $10.00 | $50,000.00 |
DisclosureSEC source: 0001209191-19-020126 · doc4.xml · nonDerivative · entry 2 Yi Kathy · CIK 0001697802 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,512 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F2 · balance_after: Includes 4,833 shares subject to restricted stock units granted on January 24, 2018 that will vest in two (2) remaining equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Additionally, this amount includes 19,250 shares subject to restricted stock units granted on February 25, 2019 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 23:35 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,000 | $4.55 | $22,750.00 |
DisclosureSEC source: 0001209191-19-020126 · doc4.xml · nonDerivative · entry 1 Yi Kathy · CIK 0001697802 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 01:21 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-19-017164 · doc4.xml · derivative · entry 3 Yi Kathy · CIK 0001697802 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 5,000 shares Expires 2027-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from February 27, 2017, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 01:21 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,000 | $10.00 | $50,000.00 |
DisclosureSEC source: 0001209191-19-017164 · doc4.xml · nonDerivative · entry 2 Yi Kathy · CIK 0001697802 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,512 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F2 · balance_after: Includes 4,833 shares subject to restricted stock units granted on January 24, 2018 that will vest in two (2) remaining equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Additionally, this amount includes 19,250 shares subject to restricted stock units granted on February 25, 2019 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 01:21 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,000 | $4.55 | $22,750.00 |
DisclosureSEC source: 0001209191-19-017164 · doc4.xml · nonDerivative · entry 1 Yi Kathy · CIK 0001697802 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2019 Filed Feb 28, 2019 01:18 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right-to-Buy) · Derivative | 115,500 | $0.00 Strike: $9.03 | $0.00 |
DisclosureSEC source: 0001209191-19-014297 · doc4.xml · derivative · entry 2 Yi Kathy · CIK 0001697802 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,500 Underlying: Common Stock · 115,500 shares Expires 2029-02-24 F2 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2019 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| February 25, 2019 Filed Feb 28, 2019 01:18 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 19,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-014297 · doc4.xml · nonDerivative · entry 1 Yi Kathy · CIK 0001697802 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,512 F1 · balance_after: Represents 19,250 shares subject to restricted stock units granted on February 25, 2019 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Additionally, this amount includes 4,833 shares subject to restricted stock units granted on January 24, 2018 that will vest in two (2) remaining equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Read SEC document |
| January 24, 2019 Filed Jan 28, 2019 22:45 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 988 | $11.10 | $10,966.80 |
DisclosureSEC source: 0001209191-19-005619 · doc4.xml · nonDerivative · entry 1 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,262 F1 · shares: Represents shares underlying the portion of the restricted stock unit grant that vested on January 24, 2019 surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on January 24, 2019 of $11.10/share, pursuant to the terms of the Issuer's 2013 Stock Incentive Plan. F2 · balance_after: Includes 1,429 shares resulting from the January 24, 2019 vesting of Reporting Person's January 24, 2018 restricted stock unit grant and 4,833 shares subject to such restricted stock unit grant that will vest in two (2) additional equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 21:08 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-19-003926 · doc4.xml · derivative · entry 3 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 5,000 shares Expires 2027-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from February 27, 2017, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 21:08 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,000 | $11.04 | $55,200.00 |
DisclosureSEC source: 0001209191-19-003926 · doc4.xml · nonDerivative · entry 2 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,250 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F2 · balance_after: Represents 7,250 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 21:08 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,000 | $4.55 | $22,750.00 |
DisclosureSEC source: 0001209191-19-003926 · doc4.xml · nonDerivative · entry 1 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2018 Filed Dec 18, 2018 22:35 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-18-063265 · doc4.xml · derivative · entry 3 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 5,000 shares Expires 2027-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from February 27, 2017, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| December 17, 2018 Filed Dec 18, 2018 22:35 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,000 | $11.44 | $57,200.00 |
DisclosureSEC source: 0001209191-18-063265 · doc4.xml · nonDerivative · entry 2 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,250 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F2 · balance_after: Represents 7,250 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| December 17, 2018 Filed Dec 18, 2018 22:35 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,000 | $4.55 | $22,750.00 |
DisclosureSEC source: 0001209191-18-063265 · doc4.xml · nonDerivative · entry 1 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 22:16 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-18-059015 · doc4.xml · derivative · entry 3 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 5,000 shares Expires 2027-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from February 27, 2017, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 22:16 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,000 | $10.00 | $50,000.00 |
DisclosureSEC source: 0001209191-18-059015 · doc4.xml · nonDerivative · entry 2 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,250 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F2 · balance_after: Represents 7,250 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 22:16 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,000 | $4.55 | $22,750.00 |
DisclosureSEC source: 0001209191-18-059015 · doc4.xml · nonDerivative · entry 1 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2018 Filed Oct 16, 2018 23:25 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-18-055200 · doc4.xml · derivative · entry 3 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 5,000 shares Expires 2027-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from February 27, 2017, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| October 15, 2018 Filed Oct 16, 2018 23:25 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,000 | $13.97 | $69,850.00 |
DisclosureSEC source: 0001209191-18-055200 · doc4.xml · nonDerivative · entry 2 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,250 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F2 · balance_after: Represents 7,250 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| October 15, 2018 Filed Oct 16, 2018 23:25 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,000 | $4.55 | $22,750.00 |
DisclosureSEC source: 0001209191-18-055200 · doc4.xml · nonDerivative · entry 1 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 21:06 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-18-051500 · doc4.xml · derivative · entry 3 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 5,000 shares Expires 2027-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from February 27, 2017, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 21:06 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,000 | $14.66 | $73,284.50 |
DisclosureSEC source: 0001209191-18-051500 · doc4.xml · nonDerivative · entry 2 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,250 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F2 · price: The price reported is a weighted average price. The shares were sold at prices ranging from $14.50 to $14.95. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Represents 7,250 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 21:06 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,000 | $4.55 | $22,750.00 |
DisclosureSEC source: 0001209191-18-051500 · doc4.xml · nonDerivative · entry 1 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 20:17 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-18-047359 · doc4.xml · derivative · entry 3 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 5,000 shares Expires 2027-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from February 27, 2017, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 20:17 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,000 | $15.39 | $76,951.50 |
DisclosureSEC source: 0001209191-18-047359 · doc4.xml · nonDerivative · entry 2 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,250 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F2 · price: The price reported is a weighted average price. The shares were sold at prices ranging from $15.20 to $15.65. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Represents 7,250 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 20:17 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,000 | $4.55 | $22,750.00 |
DisclosureSEC source: 0001209191-18-047359 · doc4.xml · nonDerivative · entry 1 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 20:16 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-18-042845 · doc4.xml · derivative · entry 3 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 5,000 shares Expires 2027-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from February 27, 2017, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 20:16 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,000 | $14.77 | $73,860.00 |
DisclosureSEC source: 0001209191-18-042845 · doc4.xml · nonDerivative · entry 2 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,250 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F2 · price: The price reported is a weighted average price. The shares were sold at prices ranging from $14.45 to $15.10. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Represents 7,250 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 20:16 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,000 | $4.55 | $22,750.00 |
DisclosureSEC source: 0001209191-18-042845 · doc4.xml · nonDerivative · entry 1 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 23:43 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-18-038208 · doc4.xml · derivative · entry 3 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 5,000 shares Expires 2027-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from February 27, 2017, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 23:43 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,000 | $15.67 | $78,365.00 |
DisclosureSEC source: 0001209191-18-038208 · doc4.xml · nonDerivative · entry 2 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,250 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F2 · price: The price reported is a weighted average price. The shares were sold at prices ranging from $15.45 to $15.825. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Represents 7,250 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 23:43 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,000 | $4.55 | $22,750.00 |
DisclosureSEC source: 0001209191-18-038208 · doc4.xml · nonDerivative · entry 1 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2018 Filed May 16, 2018 22:38 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-18-030691 · doc4.xml · derivative · entry 3 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 5,000 shares Expires 2027-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from February 27, 2017, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| May 15, 2018 Filed May 16, 2018 22:38 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,000 | $15.38 | $76,920.00 |
DisclosureSEC source: 0001209191-18-030691 · doc4.xml · nonDerivative · entry 2 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,250 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F2 · price: The price reported is a weighted average price. The shares were sold at prices ranging from $15.20 to $15.55. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Represents 7,250 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| May 15, 2018 Filed May 16, 2018 22:38 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,000 | $4.55 | $22,750.00 |
DisclosureSEC source: 0001209191-18-030691 · doc4.xml · nonDerivative · entry 1 Yi Kathy · CIK 0001697802 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.